STAT Plus: Debates over biosimilar uptake notwithstanding, sales growth should accelerate by 2024
ADOBE
“The key takeaway is that we have a trajectory that certainly seems to be accelerating,” said David Kaplan, director of the health care group at S&P.
.png)
No hay comentarios:
Publicar un comentario